sluit venster

Log in

Gebruikersnaam Wachtwoord Gebruikersnaam en/of wachtwoord vergeten? Gebruikersnaam en wachtwoord aanvragen

Zoek in de HOVON website

Let op!
Mogelijk ziet u niet alle beschikbare info op deze pagina, omdat u niet bent ingelogd, of omdat u niet de juiste privileges heeft.

Clinical picture: NHL (Non Hodgkin Lymphoma)

Trial: HOVON 152 DLBCL


News
1. Overview
Study details
2. Patient eligibility criteria
3. Registration (& randomization) of patients
4. Participating parties
5. Participating sites
6. Instruction videos
7. Download documentation / forms


return to top

News


HO 152 news

study is in preparation

1. Overview



Summary

Patients with high grade B cell lymphoma th at harbor a MYC combined with a BCL2 and/or a BCL6 rearrangement (double-hit or triple-hit high-grade B cell lymphoma, DH/TH HGBL) have a dismal prognosis following standard treatment with R-CHOP. Intensified treatment with DA-EPOCH-R induces higher complete metabolic remission (CMR) rates and prolongs disease free survival (DFS) as compared to R-CHOP and other intensified chemotherapy regimens, but relapses do often occur and improved overall survival (OS) has not been achieved.
Check-point inhibitors like nivolumab show promising results in relapsed Non-Hodgkin lymphoma. We expect to induce deeper remissions with DA-EPOCH-R than with R-CHOP, providing a good platform for immune checkpoint inhibition to consolidate complete remission or to induce remission in minimal residual disease (MRD) positive patients, resulting in better DFS.


Status

planned


Members

HOVON



Study details



Type of study

Prospective Phase II study


Echelon level

Level D


Echelon level specification

Limited nr of sites


Type of monitoring for this study

Site evaluation visits


Target number of patients

102


2. Patient eligibility criteria



3. Registration (& randomization) of patients



4. Participating parties



5. Participating sites



6. Instruction videos



7. Download documentation / forms




return to top